ESTRO 2024 - Abstract Book

S557

Clinical - Breast

ESTRO 2024

Conclusion:

MHF demonstrates comparable or improved side effects, cosmetic profiles, and QoL relative to PF without compromising oncologic outcomes. Fewer RCTs compared MHF to UHF, but their toxicity and oncologic effectiveness so far appear similar.